Loading...
NPI 1760930697 · Fort Pierce, FL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Dynix Diagnostix is a clinical medical laboratory provider located in Fort Pierce, Florida. This profile covers 57 Medicare and 35 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Dynix Diagnostix |
| Address | 2260 N Us Highway 1 |
| City | Fort Pierce |
| State | FL |
| ZIP | 34946 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | September 20, 2016 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $13.4M |
| Medicaid | $102.7K |
This lab’s Medicare business is concentrated and skewed toward a few high-revenue codes: its top 3 Medicare codes account for 57.2% of total Medicare revenue, driven primarily by K1034 which alone generates $5.8M (42.5% of Medicare revenue). That concentration indicates the operation relies heavily on a small set of services for Medicare income rather than a broad, evenly distributed test mix.
K1034 is an outlier nationally for Medicare volume and dominates this provider’s Medicare receipts. The code K1034 is listed as an "extreme outlier" (rank #81 of 30143 providers nationally, 100th percentile) and produces $5.8M in revenue, signaling unusually large scale for provision of nonprescription self‑administered COVID tests compared with typical national providers.
Alongside mass COVID test provisioning, the practice also reports substantial specialized molecular/genetic testing on Medicare. High-revenue genetic codes such as 81307 ($1.1M, $663 avg paid/claim; rank #9 of 62, 87th percentile), 81321 ($946.7K; rank #5 of 37, 89th percentile) and several other gene‑sequencing CPTs appear repeatedly in the top Medicare codes, indicating an operational mix that includes both high-volume COVID testing and high-margin molecular diagnostics.
Compared to Medicare, Medicaid is negligible in scale for this provider: lifetime Medicare revenue is $13.4M versus lifetime Medicaid revenue of $102.7K, so the business is effectively Medicare‑dominant. The very small Medicaid footprint suggests limited Medicaid contracting or low Medicaid patient utilization for the lab’s core services.
Medicaid revenue is highly concentrated in a small set of COVID-related codes: the top 3 Medicaid codes account for 97.2% of total Medicaid revenue, led by U0004 at $78.1K (76.3% of Medicaid revenue) with U0005 and 87811 contributing most of the remainder. This pattern shows the provider’s Medicaid activity is almost entirely pandemic testing rather than the broader genetic test mix seen in Medicare.
Competitive standing differs by code set: the provider is a national volume leader for K1034 (extreme outlier) and is among high-volume providers for multiple specialized genetic tests (for example, 81307 ranks #9 of 62 and 81321 ranks #5 of 37, both in the upper percentiles). In contrast, its in‑state Medicaid ranks for COVID PCR/antigen codes are middling to modest (U0004 rank #30 of 70, 58th percentile; U0005 rank #70 of 175, 60th percentile), so it is not a dominant Medicaid player in Florida.
There are additional notable above‑typical volumes in specific genetic and coagulation tests that reinforce a specialty lab profile: 81241 (Factor V Leiden) is $110.7K and ranks #4 of 55 nationally (94th percentile, "notably above typical"), and 81279 (JAK2) appears at $284.5K and ranks in the 95th percentile. These placements point to consistent, above‑typical throughput on certain hereditary and hematology-related assays.
Operational tenure is established but not long-standing compared with legacy labs: the NPI was enumerated 2016-09-20 (~10 years ago). That timeline is consistent with a relatively recent entrant that has scaled nationally on selected services (notably K1034 and specialized genetic panels) rather than a decades-old regional pathology network.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
57 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 479,230 | $10 | $5.8M |
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 1,590 | $660 | $1.1M |
| 81321 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the phosphatase and tensin homolog, or PTEN, gene. | 1,610 | $590 | $946.7K |
| 81249 | The lab analyst performs the technical lab test to analyze known the full gene sequence of the glucose–6–phosphate dehydrogenase (G6PD) gene. | 1,520 | $590 | $894.3K |
| 81238 | The lab analyst performs the technical lab test to analyze the full gene sequence of the coagulation factor IX (F9) gene. | 1,510 | $590 | $887.3K |
| 81223 | The lab analyst performs the technical lab test to analyze the entire gene sequence for cystic fibrosis transmembrane conductance regulator gene, also known as CFTR. | 1,520 | $490 | $742.8K |
| 81334 | The lab analyst performs the technical lab test to detect the presence of specific changes in the runt related transcription factor 1 (RUNX) gene for targeted sequence analysis, such as exons 3–8. | 1,560 | $320 | $504.5K |
| 81311 | The lab analyst performs the technical lab test to analyze variants in exon 2, such as codons 12 and 13, and exon 3, such as codon 61, for the neuroblastoma RAS viral, v–ras, oncogene homolog, also… | 1,560 | $290 | $453.3K |
| 81320 | The lab analyst performs the technical lab test to detect the presence of common changes in the phospholipase C gamma 2 gene (PLCG2). | 1,560 | $290 | $447K |
| 81279 | The lab analyst performs the technical lab test on a specimen such as blood to analyze specific gene sequences of the JAK2 (Janus kinase 2) gene, such as exons 12 and 13, which may be associated with… | 1,560 | $180 | $284.5K |
Showing 1–10 of 57
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 57 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
57 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81307 | 4 | 30 | 320 | $660 | $508.3K |
| 81321 | 4 | 30 | 430 | $580 | $467.7K |
| 81238 | 4 | 20 | 330 | $590 | $440.3K |
| 81162 | 9 | 20 | 100 | $1,780 | $403.3K |
| 81249 | 3 | 20 | 290 | $590 | $383.1K |
| 81223 | 4 | 20 | 340 | $490 | $329.3K |
| 81351 | 14 | 20 | 210 | $630 | $307.8K |
| 81334 | 4 | 20 | 390 | $320 | $295.7K |
| 81311 | 3 | 20 | 270 | $290 | $213K |
| 81320 | 4 | 20 | 210 | $290 | $210.6K |
Showing 1–10 of 57
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
35 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 1,400 | $60 | $78.1K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 890 | $10 | $10.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1,190 | $10 | $10.7K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,140 | $1 | $2.3K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 290 | $1 | $290 |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 220 | $1 | $220 |
| 82746 | The lab analyst measures the folic acid level in serum to determine if there is a deficiency. Folic acid deficiency is attributed to many conditions such as malabsorption, Crohn’s disease, celiac… | 30 | $1 | $30 |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 10 | $0 | $0 |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 170 | $0 | $0 |
| 82040 | The lab analyst performs a quantitative measurement on a serum, plasma, or whole blood specimen for albumin. | 130 | $0 | $0 |
Showing 1–10 of 35
How this provider's Medicaid billing volume and revenue compare to other Florida providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Florida median
35 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 30 | 70 | 500 | $30 | $231.8K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 517 | 640 | 4,400 | $10 | $193.4K |
| 84520 | The lab analyst performs a test to measure the amount of urea nitrogen in patient blood. | 246 | 300 | 1,170 | $60 | $186K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 70 | 70 | 180 | $20 | $178K |
| 82310 | The lab analyst measures the calcium level, primarily on a serum sample. | 158 | 220 | 880 | $50 | $151.3K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 26 | 50 | 360 | $40 | $96.2K |
| 84155 | The lab analyst performs the technical lab test to quantitate total protein in a serum, plasma, or whole blood specimen using one of several assay methods, excluding refractometry. Total protein is a… | 194 | 250 | 680 | $60 | $94.3K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 596 | 820 | 1,430 | $1 | $92.8K |
| 82040 | The lab analyst performs a quantitative measurement on a serum, plasma, or whole blood specimen for albumin. | 179 | 240 | 580 | $60 | $92.3K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 259 | 340 | 220 | $10 | $67.4K |
Showing 1–10 of 35
Other providers in the same ZIP code as Dynix Diagnostix, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Rg Ambulance Service, Inc. | FL | Land Ambulance | $1.2M | $1.1M |
| Rocky Mountain Holdings, LLC | FL | Air Ambulance | $692.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.